A roundup of the latest market developments from the pipelines of the pharmaceutical majors, featuring news from Teva Pharmaceutical Industries.

Editor’s Note: This article was updated on a continuous basis for news announced from Wednesday, January 31, 2017 to Tuesday, February 6, 2017.

EMA Accepts Teva’s MAA for Migraine Drug
The European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for Teva Pharmaceutical Industries’ fremanezumab, an anti-calcitonin gene-related peptide (CGRP) antibody, for preventing episodic and chronic migraine in adults.

Fremanezumab is a fully humanized monoclonal antibody targeting the CGRP ligand, a target in migraine.

Source: Teva Pharmaceutical Industries